Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

August 31, 2006

Study Completion Date

December 31, 2006

Conditions

Glycogen Storage Disease Type IIGlycogenosis 2

Interventions

BIOLOGICAL

Myozyme

20 mg/kg

Trial Locations (8)

Colorado Health Science Center, Aurora

Galichia Heart Hospital, Wichita

Freeman Health Systems, Joplin

The Women's and Children's Hospital of Buffalo, Buffalo

North Shore University Hospital, Manhasset

Macoumb/Oakland Adult Medicine, Rochester Hills

Riverside Regional Medical Center, Newport News

Genzyme Medical Information, Cambridge

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00074932 - Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease | Biotech Hunter | Biotech Hunter